Single Center, Phase 2B, Randomized, Double-Blind, Placebo, Individual Components, and 2-Doses, Controlled Study to Assess the Efficacy and Safety of a Single Dose of ALLOD-2 in the Acute Treatment of Migraine (ANODYNE-1)
Phase of Trial: Phase II/III
Latest Information Update: 30 Nov 2017
At a glance
- Drugs ALLOD 2 (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms ANODYNE1
- Sponsors Allodynic Therapeutics
- 29 Oct 2017 Planned number of patients changed from 150 to 120.
- 12 Aug 2017 Planned End Date changed from 1 Feb 2018 to 1 Apr 2018.
- 12 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.